Exagen (XGN) Projected to Post Quarterly Earnings on Tuesday

Exagen (NASDAQ:XGN) is expected to announce its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Exagen to post earnings of ($0.19) per share and revenue of $18.34 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:30 AM ET.

Exagen (NASDAQ:XGN) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.06. The company had revenue of $19.94 million for the quarter, compared to analyst estimates of $17.80 million. Exagen had a negative net margin of 26.61% and a negative return on equity of 104.46%. On average, analysts expect Exagen to post ($0.69) EPS for the current fiscal year and ($0.56) EPS for the next fiscal year.

Exagen Stock Performance

Shares of NASDAQ:XGN opened at $7.47 on Tuesday. The company’s fifty day moving average is $7.81 and its 200 day moving average is $4.99. Exagen has a 52 week low of $2.59 and a 52 week high of $12.23. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of 1.96.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. TD Cowen raised their price objective on Exagen from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. BTIG Research boosted their target price on Exagen from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Canaccord Genuity Group increased their target price on Exagen from $9.00 to $11.00 and gave the company a “buy” rating in a report on Monday, October 19th. B. Riley Financial began coverage on Exagen in a research report on Friday, September 11th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Exagen in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.12.

Insiders Place Their Bets

In other Exagen news, CEO John Aballi sold 34,294 shares of the firm’s stock in a transaction on Friday, October 16th. The shares were sold at an average price of $7.87, for a total value of $269,893.78. Following the sale, the chief executive officer owned 805,540 shares of the company’s stock, valued at $6,339,599.80. This trade represents a 4.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Jorey Chernett acquired 14,000 shares of the firm’s stock in a transaction on Monday, October 19th. The stock was purchased at an average price of $7.46 per share, for a total transaction of $104,440.00. Following the transaction, the insider directly owned 2,618,540 shares of the company’s stock, valued at approximately $19,534,308.40. This trade represents a 0.54% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 10.40% of the company’s stock.

About Exagen

Exagen Inc is a commercial-stage diagnostic company focused on improving the diagnosis and management of autoimmune and rheumatic diseases. The company develops and commercializes blood tests that help physicians identify autoimmune disease, distinguish among related conditions and monitor disease activity over time.

Its principal product family is AVISE, which includes the AVISE CTD and AVISE Lupus tests, as well as monitoring and specialty tests used in the evaluation of systemic lupus erythematosus and other connective-tissue diseases.